US FDA Requests More Information, Needs More Time To Review Birth Control OTC Switch Proposal
Executive Summary
FDA decision on Perrigo subsidiary’s proposal for first US OTC daily oral contraceptive is extended 90 days with the postponement of an advisory panel meeting. Agency requested additional information related to OTC switch application of 0.075-mg norgestrel initially submitted in July.
You may also be interested in...
After ‘Most Difficult Part’ Of Opill Decision, FDA Expects Pre-Study Tests Of Self-Reporting Methods
“Improbable results” in HRA’s actual use study data provide lesson for FDA and sponsors of future OTC switch applications on designing actual use studies, according to summary of agency’s review of HRA’s sNDA for the first US OTC oral contraceptive.
Biden Calls For Expanding Access To Reproductive Health Care, Including OTC Oral Contraceptives
President’s “Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services” is third on reproductive health care access since Supreme Court’s Dobbs decision allowing states to regulate access to abortion services.
Biden Calls For Expanding Access To Reproductive Health Care, Including OTC Oral Contraceptives
President’s “Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services” is third on reproductive health care access since Supreme Court’s Dobbs decision allowing states to regulate access to abortion services.